{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:16:24Z","timestamp":1792664184768,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3,14]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>GlycoPEGylated FVIII (N8-GP) demonstrates the same efficacy and prolonged effect in animal models as native FVIII. Circulatory half-life of glycoPEGylated FVIII (N8-GP) is prolonged by approximately twofold in several species.<\/jats:p>","DOI":"10.1182\/blood-2012-01-407494","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T01:14:40Z","timestamp":1358558080000},"page":"2108-2116","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":114,"title":["A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models"],"prefix":"10.1182","volume":"121","author":[{"given":"Henning R.","family":"Stennicke","sequence":"first","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Kjalke","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte M.","family":"Karpf","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer W.","family":"Balling","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Elm","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"\u00d8vlisen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte N.","family":"Gudme","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Persson","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Hilden","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Pelzer","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Rahbek-Nielsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Jespersgaard","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Are","family":"Bogsnes","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette A.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Peschke","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Kappers","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Rode","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Thim","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Tranholm","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Ezban","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva H. N.","family":"Olsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren E.","family":"Bj\u00f8rn","sequence":"additional","affiliation":[{"name":"Novo Nordisk, M\u00e5l\u00f8v, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111810225563400_B1","first-page":"s4","article-title":"Primary prophylaxis in children with haemophilia.","volume":"6","author":"Coppola","year":"2008","journal-title":"Blood Transfus"},{"key":"2019111810225563400_B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2007.01500.x","article-title":"Prophylaxis in adults with haemophilia.","volume":"13","author":"Hay","year":"2007","journal-title":"Haemophilia"},{"issue":"6","key":"2019111810225563400_B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111810225563400_B4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals.","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2019111810225563400_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425240802650568","article-title":"PEG-modified biopharmaceuticals.","volume":"6","author":"Bailon","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"2019111810225563400_B6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.copbio.2011.05.507","article-title":"Polymer therapeutics as nanomedicines: new perspectives.","volume":"22","author":"Duncan","year":"2011","journal-title":"Curr Opin Biotechnol"},{"issue":"10","key":"2019111810225563400_B7","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.","volume":"97","author":"Fishburn","year":"2008","journal-title":"J Pharm Sci"},{"issue":"2","key":"2019111810225563400_B8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.","volume":"116","author":"Mei","year":"2010","journal-title":"Blood"},{"key":"2019111810225563400_B9","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0049-3848(12)70003-8","article-title":"Pioneering designs for recombinant coagulation factors.","volume":"128","author":"Schulte","year":"2011","journal-title":"Thromb Res"},{"issue":"3","key":"2019111810225563400_B10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00063030-200620030-00002","article-title":"Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.","volume":"20","author":"Dumont","year":"2006","journal-title":"BioDrugs"},{"issue":"13","key":"2019111810225563400_B11","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111810225563400_B12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/glycob\/cwl004","article-title":"GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.","volume":"16","author":"DeFrees","year":"2006","journal-title":"Glycobiology"},{"issue":"5","key":"2019111810225563400_B13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1160\/TH08-04-0268","article-title":"Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives.","volume":"100","author":"Stennicke","year":"2008","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111810225563400_B14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2516.2009.02135.x","article-title":"Purification and characterization of a new recombinant factor VIII (N8).","volume":"16","author":"Thim","year":"2010","journal-title":"Haemophilia"},{"issue":"6","key":"2019111810225563400_B15","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2516.2011.02495.x","article-title":"Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE\u00ae)\u2014an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.","volume":"17","author":"Martinowitz","year":"2011","journal-title":"Haemophilia"},{"issue":"1","key":"2019111810225563400_B16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2011.10.001","article-title":"Requirements for immune recognition and processing of factor VIII by antigen-presenting cells.","volume":"26","author":"van Haren","year":"2012","journal-title":"Blood Rev"},{"issue":"pt 3","key":"2019111810225563400_B17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/BA20040144","article-title":"Cloning, expression and characterization of a sialidase gene from Arthrobacter ureafaciens.","volume":"41","author":"Christensen","year":"2005","journal-title":"Biotechnol Appl Biochem"},{"issue":"2","key":"2019111810225563400_B18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0014-5793(94)00941-4","article-title":"NMR solution structure of the recombinant tick anticoagulant protein (rTAP), a factor Xa inhibitor from the tick Ornithodoros moubata.","volume":"352","author":"Antuch","year":"1994","journal-title":"FEBS Lett"},{"issue":"2","key":"2019111810225563400_B19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/pro.5560040205","article-title":"NMR structure determination of tick anticoagulant peptide (TAP).","volume":"4","author":"Lim-Wilby","year":"1995","journal-title":"Protein Sci"},{"issue":"16","key":"2019111810225563400_B20","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.95.16.9524","article-title":"A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.","volume":"95","author":"Denis","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2019111810225563400_B21","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1182\/blood.V88.9.3446.bloodjournal8893446","article-title":"Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies.","volume":"88","author":"Bi","year":"1996","journal-title":"Blood"},{"key":"2019111810225563400_B22"},{"issue":"6","key":"2019111810225563400_B23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1538-7836.2008.02954.x","article-title":"Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.","volume":"6","author":"Ovlisen","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111810225563400_B24","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2516.2010.02333.x","article-title":"Functional characteristics of N8, a new recombinant FVIII.","volume":"16","author":"Christiansen","year":"2010","journal-title":"Haemophilia"},{"issue":"1","key":"2019111810225563400_B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2516.2011.02608.x","article-title":"Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.","volume":"18","author":"Elm","year":"2012","journal-title":"Haemophilia"},{"issue":"1","key":"2019111810225563400_B26","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/j.1365-2516.2009.02133.x","article-title":"A ferric chloride induced arterial injury model used as haemostatic effect model.","volume":"16","author":"M\u00f8ller","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"2019111810225563400_B27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/oxfordjournals.jbchem.a132675","article-title":"Enzymatic properties of neuraminidases from Arthrobacter ureafaciens.","volume":"86","author":"Uchida","year":"1979","journal-title":"J Biochem"},{"issue":"10","key":"2019111810225563400_B28","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1182\/blood-2002-07-2081","article-title":"Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency.","volume":"101","author":"Bovenschen","year":"2003","journal-title":"Blood"},{"issue":"34","key":"2019111810225563400_B29","doi-asserted-by":"crossref","first-page":"23734","DOI":"10.1074\/jbc.274.34.23734","article-title":"The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.","volume":"274","author":"Lenting","year":"1999","journal-title":"J Biol Chem"},{"issue":"53","key":"2019111810225563400_B30","doi-asserted-by":"crossref","first-page":"37685","DOI":"10.1074\/jbc.274.53.37685","article-title":"Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism.","volume":"274","author":"Saenko","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111810225563400_B31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jaci.2011.08.029","article-title":"Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain.","volume":"129","author":"Herczenik","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2019111810225563400_B32","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2019111810225563400_B33","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V88.8.2939.bloodjournal8882939","article-title":"Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.","volume":"88","author":"Siedlecki","year":"1996","journal-title":"Blood"},{"key":"2019111810225563400_B34","first-page":"567","article-title":"Glyco-PEGylation of FVIII reduces cellular uptake in the liver, but does not alter in vivo distribution.","volume":"9","author":"Appa","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111810225563400_B35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2006-05-022756","article-title":"VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.","volume":"109","author":"Dasgupta","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2019111810225563400_B36","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1182\/blood-2011-11-391680","article-title":"Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.","volume":"119","author":"Wroblewska","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/11\/2108\/1363618\/2108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/11\/2108\/1363618\/2108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T22:08:48Z","timestamp":1714860528000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/11\/2108\/31057\/A-novel-Bdomain-OglycoPEGylated-FVIII-N8GP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,3,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-407494","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]}}}